479 related articles for article (PubMed ID: 21078943)
21. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.
Hegde SS; Skinner R; Lewis SR; Krause KM; Blais J; Benton BM
J Antimicrob Chemother; 2010 Apr; 65(4):725-8. PubMed ID: 20139142
[TBL] [Abstract][Full Text] [Related]
22. Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF
Antimicrob Agents Chemother; 2008 Jul; 52(7):2383-8. PubMed ID: 18443115
[TBL] [Abstract][Full Text] [Related]
23. Telavancin shows superior activity to vancomycin with multidrug-resistant Staphylococcus aureus in a range of in vitro biofilm models.
Smith K; Gemmell CG; Lang S
Eur J Clin Microbiol Infect Dis; 2013 Oct; 32(10):1327-32. PubMed ID: 23624635
[TBL] [Abstract][Full Text] [Related]
24. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
Huang YT; Liao CH; Teng LJ; Hsueh PR
Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of telavancin susceptibility in isolates of Staphylococcus aureus with reduced susceptibility to vancomycin.
McMullen AR; Lainhart W; Wallace MA; Shupe A; Burnham CD
Eur J Clin Microbiol Infect Dis; 2019 Dec; 38(12):2323-2330. PubMed ID: 31446513
[TBL] [Abstract][Full Text] [Related]
26. In vitro activity of telavancin and comparators against selected groups of Gram-positive cocci.
Hope R; Chaudhry A; Adkin R; Livermore DM
Int J Antimicrob Agents; 2013 Mar; 41(3):213-7. PubMed ID: 23298432
[TBL] [Abstract][Full Text] [Related]
27. [Surveillance on gram-positive bacteria isolated from patients with hospital acquired infections or community acquired infections].
Li JT; Li Y; Wang J;
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):365-74. PubMed ID: 12820911
[TBL] [Abstract][Full Text] [Related]
28. Vancomycin tolerance in methicillin-resistant Staphylococcus aureus: influence of vancomycin, daptomycin, and telavancin on differential resistance gene expression.
Rose WE; Fallon M; Moran JJ; Vanderloo JP
Antimicrob Agents Chemother; 2012 Aug; 56(8):4422-7. PubMed ID: 22687502
[TBL] [Abstract][Full Text] [Related]
29. Pharmacodynamics of razupenem (PZ601) studied in an in vitro pharmacokinetic model of infection.
MacGowan AP; Noel A; Tomaselli S; Elliott H; Bowker K
Antimicrob Agents Chemother; 2011 Apr; 55(4):1436-42. PubMed ID: 21263054
[TBL] [Abstract][Full Text] [Related]
30. In vitro studies of the pharmacodynamics of teicoplanin against Staphylococcus aureus, Staphylococcus epidermidis and Enterococcus faecium.
Odenholt I; Löwdin E; Cars O
Clin Microbiol Infect; 2003 Sep; 9(9):930-7. PubMed ID: 14616681
[TBL] [Abstract][Full Text] [Related]
31. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of
Kebriaei R; Rice SA; Stamper KC; Rybak MJ
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670436
[TBL] [Abstract][Full Text] [Related]
32. Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections.
Pfaller MA; Rhomberg PR; Sader HS; Mendes RE; Jones RN
J Chemother; 2010 Oct; 22(5):304-11. PubMed ID: 21123152
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
Madrigal AG; Basuino L; Chambers HF
Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
[TBL] [Abstract][Full Text] [Related]
34. In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains.
LaPlante KL; Mermel LA
Antimicrob Agents Chemother; 2009 Jul; 53(7):3166-9. PubMed ID: 19451302
[TBL] [Abstract][Full Text] [Related]
35. Comparison of telavancin and vancomycin lock solutions in eradication of biofilm-producing staphylococci and enterococci from central venous catheters.
Luther MK; Mermel LA; LaPlante KL
Am J Health Syst Pharm; 2016 Mar; 73(5):315-21. PubMed ID: 26896504
[TBL] [Abstract][Full Text] [Related]
36. Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations.
Brauers J; Kresken M; Menke A; Orland A; Weiher H; Morrissey I
Int J Antimicrob Agents; 2007 Mar; 29(3):322-5. PubMed ID: 17204403
[TBL] [Abstract][Full Text] [Related]
37. Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16.
Pfaller MA; Mendes RE; Duncan LR; Flamm RK; Sader HS
J Antimicrob Chemother; 2018 Oct; 73(10):2748-2756. PubMed ID: 29982565
[TBL] [Abstract][Full Text] [Related]
38. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations.
Akins RL; Rybak MJ
Antimicrob Agents Chemother; 2001 Feb; 45(2):454-9. PubMed ID: 11158740
[TBL] [Abstract][Full Text] [Related]
39. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
Smith JR; Barber KE; Hallesy J; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162
[TBL] [Abstract][Full Text] [Related]
40. Beyond Vancomycin: The Tail of the Lipoglycopeptides.
Klinker KP; Borgert SJ
Clin Ther; 2015 Dec; 37(12):2619-36. PubMed ID: 26658277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]